Gastroenterology
Volume 129, Issue 4 , Pages 1294-1301, October 2005

Celiac Disease: Caught Between a Rock and a Hard Place

  • Frits Koning

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Frits Koning, PhD, Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, E3-Q, PO Box 9600, 2300 RC Leiden, The Netherlands.fax: (31) 71-5216751.

Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands

Received 7 January 2005; accepted 8 April 2005. published online 14 September 2005.

Celiac disease (CD) is an intestinal disorder caused by an intolerance to gluten, proteins in wheat. CD is an HLA-associated disease: virtually all patients express HLA-DQ2 or HLA-DQ8. Recent work has shown that these disease-predisposing HLA-DQ molecules bind enzymatically modified gluten peptides and these HLA-DQ peptide complexes trigger inflammatory T-cell responses in the small intestine that lead to disease. In addition, gluten induces innate immune responses that contribute to the tissue damage that is characteristic for CD. Thus, CD patients are caught between a rock and a hard place: the disease is caused by a combination of adaptive and innate immune responses that both are triggered by gluten. These findings explain the disease-inducing properties of gluten and provide valuable clues for the development of alternative treatment modalities for patients. They also may be of relevance for our understanding of other multifactorial disorders including IBD and HLA-associated autoimmune diseases.

Abbreviations used in this paper:  APC, antigen-presenting cells , CD, celiac disease , IL, interleukin , MICA, MHC class I related A protein , tTG, tissue transglutaminase

 

 Supported by grants from the European Commission (BHM4-CT98-3087 and QLK1-2000-00657), the “Stimuleringsfonds Voedingsonderzoek Leiden University Medical Centre,” the Dutch Organization for Scientific Research (ZonMW grant 912-02-028), and the Celiac Disease Consortium, an Innovative Cluster approved by the Netherlands Genomics Initiative and partially funded by the Dutch Government (BSIK03009).

PII: S0016-5085(05)01430-7

doi:10.1053/j.gastro.2005.07.030

Gastroenterology
Volume 129, Issue 4 , Pages 1294-1301, October 2005